Meropenem-vaborbactam is a carbapenem/cyclic boronic acid β-lactamase inhibitor combination primarily active against Gram-negative bacilli, including those harboring class A serine carbapenemases such as Klebsiella pneumoniae carbapenemase (KPC). A Clinical and Laboratory Standards Institute M23-A4 (Tier 2) quality control study established broth microdilution and disk diffusion ranges for reference strains. Two KPC-producing K. pneumoniae ATCC strains are recommended for quality control testing.
Introduction
The significance of multidrug-resistant Enterobacteriaceae to clinical medicine has been well documented, particularly in terms of disease incidence rates and association with poor clinical outcomes (Thaden et al., 2017) . Carbapenem-resistant Enterobacteriaceae (CRE) are viewed as an urgent threat in this context (CDC, 2013) because rates of these infections have increased globally (Sievert et al., 2013 , van Duijn et al., 2011 , invasive infections with CRE are associated with significant mortality (Tzouvelekis et al., 2012) , and options to treat these organisms have become limited (Thaden et al., 2017) . Vaborbactam (formerly RPX7009) is a cyclic boronic acid β-lactamase inhibitor designed to inactivate class A serine carbapenemases such as Klebsiella pneumoniae carbapenemase (KPC) (Hecker et al., 2015) . Castanheira et al. (2016) reported that vaborbactam restored meropenem activity against a majority of KPC-producing isolates (optimally at a concentration of 8 μg/mL). This agent was well tolerated in a phase 1 healthy-volunteer study (Griffith et al., 2016 , Wenzler et al., 2015 . A fixed-dose meropenem-vaborbactam product has completed phase 3 clinical trials for the treatment of complicated urinary tract infection (including acute pyelonephritis) and serious infection due to CRE (ClincalTrials.gov, 2016, ClincalTrials.gov, 2017). The formulation is now FDA-approved for treatment of adult patients with complicated urinary tract infection, including pyelonephritis, caused by selected Enterobacteriaceae.
This investigation established broth microdilution and disk diffusion meropenem and meropenem-vaborbactam quality control (QC) ranges for Clinical and Laboratory Standards Institute (CLSI) reference strains of Gram-positive cocci and Gram-negative bacilli. The addition of two KPC-producing K. pneumoniae reference strains [ATCC BAA-1705 (KPC-2, SHV) and ATCC BAA-2814 (KPC-3, SHV-11, TEM-1)] allows for QC of meropenem both alone and in combination with fixed concentration vaborbactam using different parts of the susceptibility dilution range. Meropenem-vaborbactam (VABOMERE™) recently received FDA approval for the treatment of complicated urinary tract infection (VABOMERE™, 2017). Broth microdilution and disk diffusion QC ranges for meropenem-vaborbactam will assist both clinical and reference laboratories in generating accurate susceptibility testing results in clinical microbiology practice.
Materials and Methods
Quality control investigations were designed using CLSI M23-A4 guidelines (CLSI, 2016) Meropenem-vaborbactam and meropenem MIC values were obtained over a minimum of 3 days by 8 independent laboratories, generating 1 MIC value per strain/medium lot for 10 replicates (240 total MIC values per reference strain and test compound). Inoculum assessment yielded mean colony counts ranging from 2.9 × 10 5 (K. pneumoniae ATCC 700603) to 4.5 × 10 5 CFU/mL (P. aeruginosa ATCC 27853). Internal quality assurance for frozen panels included analysis of P. aeruginosa ATCC 27853 against meropenem (nine replicates per laboratory) and piperacillin-tazobactam (testing range 0.06/4-32/4 μg/mL; six replicates per laboratory).
For disk diffusion testing, individual lots of meropenem-vaborbactam disks (20/10 μg) were obtained from Bio-Rad Laboratories (Hercules, CA; lot 5H0011) and the MAST Group (Bootle, Merseyside, United Kingdom; lot 357368). Mueller-Hinton agar (MHA) was obtained from Hardy Diagnostics (Santa Maria, CA; lot H11-15302), ThermoFisher (Lenexa, Ks; lot 766782), and BBL (Sparks, MD; lot 5287893). Susceptibility testing and disk diffusion QC range determinations followed CLSI guidelines (CLSI, 2015, CLSI, 2016). Meropenem-vaborbactam disk zone diameters against E. coli ATCC 25922; K. pneumoniae ATCC 700603, ATCC BAA-1705, and ATCC BAA-2814; P. aeruginosa ATCC 27853; and S. aureus ATCC 25923 were obtained by 7 laboratories over a minimum interval of 3 days, generating 1 zone diameter value per reference strain/disk lot/medium lot for 10 replicates (420 total zone diameter values per reference strain and test compound). Internal quality assurance included analysis of selected strains against 10 μg meropenem (BD lot 5147624) and 100/10 μg piperacillintazobactam disks (BD lot 5111769; 30 replicates per laboratory).
Results and Discussion
Broth microdilution quality assurance testing demonstrated that 98.8% of meropenem and 100.0% of piperacillin-tazobactam MIC values for P. aeruginosa ATCC 27853 were within QC ranges published in the CLSI M100-S27 (CLSI, 2017) document (data not shown). Three log2-dilution meropenem-vaborbactam QC ranges were characterized for S. aureus ATCC 29213 (0.03/8-0.12/8 μg/mL) and K. pneumoniae ATCC 700603 (0.015/8-0.06/8 μg/mL), accounting for ≥97.1% of all MIC values ( K. pneumoniae ATCC BAA-1705 and ATCC BAA-2814 were investigated as potential QC reference strains as the currently available strains could not adequately QC the activity of the meropenem-vaborbactam combination over meropenem alone. In addition, K. pneumoniae ATCC BAA-1705 and ATCC BAA-2814 allow for the QC of different portions of the meropenem-vaborbactam QC range. With respect to meropenem-vaborbactam, CLSI M23-A4 criteria and RangeFinder both calculated a three log2-dilution QC range of 0.12/8-0.5/8 μg/mL for K. pneumoniae ATCC 2814 (Fig. 1) A bimodal distribution of meropenem MIC values against K. pneumoniae ATCC BAA-2814 was observed (Fig. 2) , indicating a four log2-dilution QC range of 32-256 μg/mL that included 100.0% of all MIC values. With respect to K. pneumoniae ATCC BAA-1705, a four log2-dilution QC range of 8-64 μg/mL including 95.8% of all meropenem MIC values was proposed using CLSI M23-A4 criteria and RangeFinder results (Fig. 2) . Disk diffusion quality assurance demonstrated 99.8% and 100.0% of meropenem and piperacillin-tazobactam zone diameters, respectively, within CLSI-published QC ranges (CLSI, 2017). The results of two laboratories were identified by RangeFinder as statistical outliers for their modal meropenem zone diameter values for S. aureus ATCC 25923. One laboratory was identified by RangeFinder as a statistical outlier for the modal meropenem MIC value against P. aeruginosa ATCC 27853, and another laboratory was identified as a statistical outlier for the meropenem MIC value against K. pneumoniae ATCC 700603. The results of two laboratories were based on modal meropenem-vaborbactam zone diameter outliers for S. aureus ATCC 25923. The aforementioned laboratories were not excluded from subsequent analysis, as the mean and median zone diameter values (as calculated by RangeFinder) were within acceptable limits. Meropenem-vaborbactam 20/10-μg disks produced by Bio-Rad yielded slightly larger zone diameters (geometric mean difference between 0.1 and 1 mm) than disks produced by MAST.
With respect to a 20/10-μg meropenem-vaborbactam disk, zone diameter QC ranges of 32-38 mm for S. aureus ATCC 25923 (encompassing 97.6% of zone diameter values), 31-37 mm for E. coli ATCC 25922 (including 99.0% of zone diameter values), and 29-35 mm for both K. pneumoniae ATCC 700603 and P. aeruginosa ATCC 27853 (99.3% of zone diameter values inclusive in both instances) were proposed (Table 1) . These zone diameter values were derived from calculation of the 95% confidence interval around the mean (CLSI, 2016). RangeFinder corroborated all findings, with the exception of a larger proposed range for S. aureus ATCC 25923 (31-39 mm) that encompassed 99.8% of zone diameter values. For a 10-μg meropenem control disk, zone diameter QC ranges of 29-37 mm for S. aureus ATCC diameter values, respectively. Of note, the previously approved meropenem disk diffusion QC range of 28-34 mm for E. coli ATCC 25922 (encompassing 100.0% of zone diameter values; Table 1 ) was revised to 28-35 mm based on the outcome of this multilaboratory QC study (CLSI, 2017) .
In further studies to identify relevant carbapenem/β-lactamase inhibitor QC strains, a meropenem-vaborbactam disk diffusion QC range of 21-27 mm for K. pneumoniae ATCC BAA-1705 was determined (Fig. 3) . Alternatively, a RangeFinder zone diameter QC range of 22-27 mm included 100.0% of results. No skewing was observed with respect to lot of MHA used. A CLSI-derived meropenem zone diameter range of 12-18 mm included 96.2% of all zone diameter values, while a zone diameter QC range of 11-18 mm, as determined by RangeFinder (Fig. 4) , captured 99.5% of zone diameter values. However, this meropenem analysis was limited by single-lot disk testing. For K. pneumoniae ATCC BAA-2814, a CLSI M23-A4 zone diameter QC range of 16-20 mm for meropenem-vaborbactam (20/10 μg) included all zone diameter values (Fig. 3) . All K. pneumoniae ATCC BAA-2814 replicates demonstrated no meropenem inhibition zone (6 mm; single-lot disk testing), confirming the carbapenem-resistant nature of this strain. These data, as well as MIC findings (Fig. 1, Fig. 2) , ascribe value to both K. pneumoniae ATCC BAA-1705 and ATCC BAA-2814 as QC reference strains confirming both the antibacterial activity of meropenem and demonstrating the β-lactamase inhibitor activity of vaborbactam. Fig. 4 . CLSI-approved disk diffusion meropenem (10 μg) zone diameter distributions by medium lot for K. pneumoniae ATCC BAA-1705 (KPC-2) and K. pneumoniae ATCC BAA-2814 (KPC-3). Medium lot A is Remel, medium lot B is Hardy Diagnostics, and medium lot C is BBL.
The CLSI Subcommittee on Antimicrobial Susceptibility Testing approved the proposed meropenem and meropenem-vaborbactam MIC QC ranges (Table 1) for E. coli ATCC 25922 and 35218, K. pneumoniae ATCC 700603, P. aeruginosa ATCC 27853, and S. aureus ATCC 29213 in January 2015. Disk diffusion QC ranges for E. coli ATCC 25922; K. pneumoniae ATCC 700603, ATCC BAA-1705, and ATCC BAA-2814; P. aeruginosa ATCC 27853; and S. aureus ATCC 25923 were approved in June 2016. MIC QC ranges for K. pneumoniae ATCC BAA-1705 and ATCC BAA-2814 were approved in January 2017 after publication of the CLSI M100-S27 document. Values listed in Table 1 also reflect those listed in the FDA-approved formulation of meropenem-vaborbactam (VABOMERE™, 2017), with the exception of the revised MIC QC range for K. pneumoniae ATCC BAA-1705 and the newly approved MIC QC range for K. pneumoniae ATCC BAA-2814. K. pneumoniae ATCC BAA-1705 and/or K. pneumoniae ATCC BAA-2814 should be used as QC reference strains when evaluating the activity of meropenem-vaborbactam combinations as they provide QC on both the meropenem and vaborbactam components of the antimicrobial combination.
